HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

N,N-dinitrosohomopiperazine

Also Known As:

DNHP

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Nitroso Compounds: 446
  - Nitrosamines: 1539
    - N,N-dinitrosohomopiperazine: 8

Experts

1.	Gallissot, Frédéric: 2 articles (12/2009 - 08/2009)
2.	Sabaté, Jean-Philippe: 2 articles (12/2009 - 08/2009)
3.	Saillenfait, Anne-Marie: 2 articles (12/2009 - 08/2009)
4.	Ge, Ren-Shan: 1 article (10/2020)
5.	Hu, Miner: 1 article (10/2020)
6.	Huang, Tongliang: 1 article (10/2020)
7.	Ji, Haosen: 1 article (10/2020)
8.	Ye, Jianxin: 1 article (10/2020)
9.	Yuan, Xindi: 1 article (10/2020)
10.	Zhang, Kangnan: 1 article (10/2020)

Related Diseases

1.	Body Weight (Weight, Body) 05/01/2003 - "The panel evaluated only a single developmental toxicity study using a high dose (9,900 mg/kg body weight/day on gestational days 6-13) of DnHP. " 12/01/2009 - "DnHP had no significant effect on maternal body weight gain and pup weights during lactation. " 08/01/2009 - "Maternal food consumption and body weight gain were significantly reduced at 750 mg kg(-1) per day of DnHP and at the two high doses of DCHP. " 08/01/2007 - "Additionally, 20, 100, or 500 mg/kg body weight (bw)/d of 6 phthalates (DEHP, DBP, BBP, DINP, DIDP, or DnHP) or 10, 50, or 250 mg/kg bw/d of MEHP, the primary metabolite of DEHP, were also administered orally in combination with testosterone (0.4 mg/kg/d, s.c.) for 10 consecutive days, respectively. "
2.	Carcinogenesis 12/01/1982 - "The slopes of these dose responses differed between NTHP- and DNHP-treated animals, suggesting that the mechanisms of carcinogenesis by these two compounds are not identical."
3.	Fetal Weight 08/01/2009 - "DnHP caused dose-related developmental toxic effects, including marked embryo mortality at 750 mg kg(-1) per day, and presence of malformations (mainly cleft palate, eye defects and axial skeleton abnormalities) and significant decreases in fetal weight at 500 and 750 mg kg(-1) per day. "
4.	Necrosis 01/01/1985 - "In contrast, diets containing DnHP or DnOP induced accumulation of large droplets of fat around central veins leading, by 10 days, to mild centrilobular necrosis and a very slight induction of one peroxisomal enzyme and an increase in liver weight, but no significant changes in any other parameters which were affected by DEHP."
5.	Hyperplasia 10/10/2020 - "DNHP increased Leydig cell number at all doses but down-regulated the expression of Lhcgr, Hsd3b1, Hsd17b3, and Hsd11b1 in Leydig cell per se at 1000 mg/kg. DNHP elevated phosphorylation of ERK1/2 and GSK-3β at 10 mg/kg but decreased SIRT1 and PGC-1α levels at 1000 mg/kg. In conclusion, DNHP exposure causes Leydig cell hyperplasia possibly via stimulating phosphorylation of ERK1/2 and GSK-3β signaling pathways."

Related Drugs and Biologics

1.	Diethylhexyl Phthalate (DEHP)
2.	4-boronic acid benzophenone
3.	O,O'- dimethyl- O- (6- chlorobicyclo(3.2.0)heptadiene- 1,5- yl)phosphate
4.	Sirtuin 1
5.	Testosterone (Sustanon)
6.	Enzymes
7.	N-nitroso-1,2,3,6-tetrahydropyridine
8.	mono-(2-ethylhexyl)phthalate
9.	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)